LINC02466 promotes the progression of hepatocellular carcinoma through the mTOR pathway

• Published in: Discover. Oncology 2024-11, Vol.15 (1), p.623-15, Article 623
• Main Authors: Liu, Shiqian, Quan, Zhipeng, Liang, Jiaming, Wang, Fuqiang, Yan, Hao, Wang, Zhenran, Tang, Bo, Qin, Xuebin
• Format: Article
• Language: English
• Subjects: Cancer Research; HCC; Internal Medicine; LINC02466; Medicine; Medicine & Public Health; Molecular Medicine; mTOR; Oncology; Proliferation; Radiotherapy; Stem cell; Surgical Oncology
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-024-00999-x

Objective Long non-coding RNAs (lncRNAs) LINC02466 is an lncRNA newly linked to the adverse outcomes in primary liver cancer patients, and its crucial involvement in the disease's escalation. Decoding the specific role of LINC02466 in HCC progression is of great significance to provide a potential therapeutic target for HCC. Methods RT-qPCR and Western Blot techniques was used to analyze the expression levels of LINC02466 in both malignant and surrounding healthy liver tissues. CCK8 assays and colony formation experiments indicates the LINC02466's effect on the proliferation rates of liver cancer cells. Flow cytometry was pivotal in revealing its significant influence on the cell cycle of these cells. Kaplan–Meier survival analysis with log-rank tests were employed. Results The suppression of LINC02466 markedly reduces the stemness attributes of liver cancer cells, indicating a potential therapeutic target. LINC02466 overexpression significantly increased tumor growth rates and final volumes. Further research indicated that LINC02466 significantly influences liver cancer progression through regulating the mTOR signaling pathway. Conclusion LINC02466 regulating cell proliferation, the cell cycle, and stemness characteristics via the mTOR pathway, suggesting LINC02466 as a potential therapeutic target for primary liver cancer.